| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Thomas J Raedler, Michael B Knable, Douglas W Jones, Richard A Urbina, Michael F Egan, Daniel R Weinberge. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 8. 2003-09-12. PMID:12799613. |
eight schizophrenia patients underwent a total of 12 [i-123]iqnb spect scans after treatment with low to moderate doses of clozapine (mean 210 mg/day, range 50-450 mg/day). |
2003-09-12 |
2023-08-12 |
human |
| Margaret G Woerner, Delbert G Robinson, Jose Ma J Alvir, Brian B Sheitman, Jeffrey A Lieberman, John M Kan. Clozapine as a first treatment for schizophrenia. The American journal of psychiatry. vol 160. issue 8. 2003-09-05. PMID:12900316. |
clozapine as a first treatment for schizophrenia. |
2003-09-05 |
2023-08-12 |
Not clear |
| Margaret G Woerner, Delbert G Robinson, Jose Ma J Alvir, Brian B Sheitman, Jeffrey A Lieberman, John M Kan. Clozapine as a first treatment for schizophrenia. The American journal of psychiatry. vol 160. issue 8. 2003-09-05. PMID:12900316. |
the authors' goal was to explore whether clozapine given as the first antipsychotic treatment favorably affects the course of schizophrenia. |
2003-09-05 |
2023-08-12 |
Not clear |
| D Cohen, C C Gispen-de Wie. [Schizophrenia and diabetes mellitus: not an improbable combination]. Nederlands tijdschrift voor geneeskunde. vol 147. issue 21. 2003-08-06. PMID:12811967. |
three male schizophrenia patients, aged 41, 40 and 61 years respectively, who had undergone treatment without a satisfactory result, were treated with the antipsychotic clozapine. |
2003-08-06 |
2023-08-12 |
Not clear |
| Shailesh Kumar, Bradley Ng, William Howi. The improvement of obsessive- compulsive symptoms in a patient with schizophrenia treated with clozapine. Psychiatry and clinical neurosciences. vol 57. issue 2. 2003-07-28. PMID:12667173. |
the improvement of obsessive- compulsive symptoms in a patient with schizophrenia treated with clozapine. |
2003-07-28 |
2023-08-12 |
Not clear |
| David Pickar, John J Bartk. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. The American journal of psychiatry. vol 160. issue 6. 2003-07-23. PMID:12777272. |
effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. |
2003-07-23 |
2023-08-12 |
Not clear |
| Christian Haasen, Martin Lambert, Oktay Yagdiran, Anne Karow, Michael Krausz, Dieter Nabe. Comorbidity of schizophrenia and galactosemia: effective clozapine treatment with weight gain. International clinical psychopharmacology. vol 18. issue 2. 2003-07-15. PMID:12598824. |
comorbidity of schizophrenia and galactosemia: effective clozapine treatment with weight gain. |
2003-07-15 |
2023-08-12 |
Not clear |
| Christian Haasen, Martin Lambert, Oktay Yagdiran, Anne Karow, Michael Krausz, Dieter Nabe. Comorbidity of schizophrenia and galactosemia: effective clozapine treatment with weight gain. International clinical psychopharmacology. vol 18. issue 2. 2003-07-15. PMID:12598824. |
our unique case report of a patient with comorbid galactosemia and schizophrenia is an interesting example of weight gain being a positive side-effect of clozapine, not necessarily associated with increased appetite and higher caloric intake. |
2003-07-15 |
2023-08-12 |
Not clear |
| Adrienne C Lahti, Henry H Holcomb, Martin A Weiler, Deborah R Medoff, Carol A Tamming. Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biological psychiatry. vol 53. issue 7. 2003-07-11. PMID:12679238. |
using positron emission tomography (pet) with (15)o water, we compared regional cerebral blood flow (rcbf) patterns induced by clozapine or haloperidol in individuals with schizophrenia. |
2003-07-11 |
2023-08-12 |
Not clear |
| Andy Duggan, Juliet Warner, Martin Knapp, Robert Kerwi. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. The British journal of psychiatry : the journal of mental science. vol 182. 2003-07-10. PMID:12777341. |
modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the uk. |
2003-07-10 |
2023-08-12 |
Not clear |
| Leslie R H Drew, Kathleen M Griffiths, Donna M Hodgso. A five year follow-up study of the use of clozapine in community practice. The Australian and New Zealand journal of psychiatry. vol 36. issue 6. 2003-06-25. PMID:12406120. |
to present information about the value of clozapine in treatment-resistant schizophrenia. |
2003-06-25 |
2023-08-12 |
Not clear |
| Eugene H Makela, William D Cutlip, James M Stevenson, Jason M Weimer, Ehab S Abdallah, Raja S Akhtar, Ahmed S Aboraya, Erdogan Gune. Branded versus generic clozapine for treatment of schizophrenia. The Annals of pharmacotherapy. vol 37. issue 3. 2003-06-20. PMID:12639161. |
branded versus generic clozapine for treatment of schizophrenia. |
2003-06-20 |
2023-08-12 |
Not clear |
| Alan I Green, Melinda S Salomon, Mark J Brenner, Kimberly Rawlin. Treatment of schizophrenia and comorbid substance use disorder. Current drug targets. CNS and neurological disorders. vol 1. issue 2. 2003-06-18. PMID:12769622. |
while the typical antipsychotics do not limit the comorbid substance use, and may actually worsen it, preliminary data suggest the novel antipsychotic clozapine may have the unusual ability to dramatically decrease alcohol and other substance use in patients with schizophrenia. |
2003-06-18 |
2023-08-12 |
Not clear |
| Staffan Hägg, Staffan Rosenius, Olav Spigse. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. International clinical psychopharmacology. vol 18. issue 3. 2003-06-17. PMID:12702898. |
we describe three patients with schizophrenia who developed granulocytopenia or agranulocytosis during treatment with clozapine and who did not respond to other antipsychotics. |
2003-06-17 |
2023-08-12 |
Not clear |
| Jeffrey A Lieberman, Michael Phillips, Hongbin Gu, Scott Stroup, Peiyan Zhang, Lan Kong, Zhongfu Ji, Gary Koch, Robert M Hame. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 5. 2003-06-11. PMID:12700715. |
atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. |
2003-06-11 |
2023-08-12 |
human |
| Jeffrey A Lieberman, Michael Phillips, Hongbin Gu, Scott Stroup, Peiyan Zhang, Lan Kong, Zhongfu Ji, Gary Koch, Robert M Hame. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 5. 2003-06-11. PMID:12700715. |
this flexible-dose study examined efficacy and safety in a randomized, double-blind, 52-week trial, comparing chlorpromazine (cpz) and clozapine (clz) in treatment naive patients experiencing their first episode of schizophrenia. |
2003-06-11 |
2023-08-12 |
human |
| Naoe Okamura, Kenji Hashimoto, Nobuhisa Kanahara, Eiji Shimizu, Chikara Kumakiri, Naoya Komatsu, Masaomi Iy. Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. European journal of pharmacology. vol 461. issue 2-3. 2003-05-23. PMID:12586203. |
an atypical antipsychotic drug, zotepine, which is pharmacologically and clinically related to clozapine, has unique therapeutic effects on patients with schizophrenia. |
2003-05-23 |
2023-08-12 |
rat |
| P Garlipp, O Rosenthal, H Haltenhof, W Machleid. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. Journal of psychopharmacology (Oxford, England). vol 16. issue 4. 2003-05-19. PMID:12503844. |
the development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. |
2003-05-19 |
2023-08-12 |
Not clear |
| P Garlipp, O Rosenthal, H Haltenhof, W Machleid. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. Journal of psychopharmacology (Oxford, England). vol 16. issue 4. 2003-05-19. PMID:12503844. |
clozapine, the first atypical antipsychotic, is indicated for the treatment of therapy-resistant schizophrenia. |
2003-05-19 |
2023-08-12 |
Not clear |
| Verner J Knott, Alain LaBelle, Barry Jones, Colleen Mahone. EEG coherence following acute and chronic clozapine in treatment-resistant schizophrenics. Experimental and clinical psychopharmacology. vol 10. issue 4. 2003-05-15. PMID:12498341. |
eeg coherence in slow (delta and theta) frequencies was assessed in 17 treatment-resistant people with schizophrenia at baseline, 2 hr after their first oral dose (25 mg) and after 6 weeks of clozapine treatment. |
2003-05-15 |
2023-08-12 |
human |